Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SKYE
Upturn stock ratingUpturn stock rating

Skye Bioscience, Inc. Common Stock (SKYE)

Upturn stock ratingUpturn stock rating
$4.61
Last Close (24-hour delay)
Profit since last BUY101.31%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: SKYE (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $15.5

1 Year Target Price $15.5

Analysts Price Target For last 52 week
$15.5 Target price
52w Low $1.14
Current$4.61
52w High $7.47

Analysis of Past Performance

Type Stock
Historic Profit 99.97%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 142.84M USD
Price to earnings Ratio -
1Y Target Price 15.5
Price to earnings Ratio -
1Y Target Price 15.5
Volume (30-day avg) 7
Beta 1.67
52 Weeks Range 1.14 - 7.47
Updated Date 07/5/2025
52 Weeks Range 1.14 - 7.47
Updated Date 07/5/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.83

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -28.04%
Return on Equity (TTM) -47.27%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 84026052
Price to Sales(TTM) -
Enterprise Value 84026052
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.56
Shares Outstanding 30984400
Shares Floating 16089248
Shares Outstanding 30984400
Shares Floating 16089248
Percent Insiders 1.44
Percent Institutions 80.79

ai summary icon Upturn AI SWOT

Skye Bioscience, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Skye Bioscience, Inc. (SKYE) is a biopharmaceutical company focused on developing proprietary cannabinoid-based pharmaceutical therapies. Originally founded as Emerald Bioscience, the company shifted its focus and rebranded. The company's history includes research and development efforts in cannabinoid therapeutics for glaucoma and other diseases.

business area logo Core Business Areas

  • Pharmaceutical Development: Development of cannabinoid-derived drug candidates for various therapeutic applications, primarily focusing on glaucoma.
  • Research and Development: Preclinical and clinical research to advance cannabinoid therapeutics.

leadership logo Leadership and Structure

As of the last update, the executive team consists of key personnel in research, development, and finance. Skye Bioscience operates with a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • SBI-100 Ophthalmic Emulsion: A proprietary formulation of a synthetic cannabinoid derivative designed to reduce intraocular pressure for the treatment of glaucoma. It is currently in clinical trials. Competitors include traditional glaucoma medications (e.g., prostaglandins, beta-blockers) from companies like Allergan (ABBV) and Novartis (NVS). Market share/revenue for this product is currently $0.00, as it is under development.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically the segment focused on ophthalmic diseases like glaucoma, is competitive. There is growing interest in novel therapies that can address unmet needs in glaucoma treatment.

Positioning

Skye Bioscience is positioned as a company developing innovative cannabinoid-based therapeutics. The company is attempting to develop drugs that improve on the efficacy and safety of existing treatments.

Total Addressable Market (TAM)

The global glaucoma market is projected to reach $5.9 billion by 2028. Skye Bioscience's position relies on securing a share of this large market through novel therapeutic options.

Upturn SWOT Analysis

Strengths

  • Novel cannabinoid-based therapeutic approach
  • Proprietary drug formulation
  • Focus on unmet needs in glaucoma treatment

Weaknesses

  • Limited financial resources
  • Early stage of clinical development
  • High regulatory hurdles

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Expansion into other therapeutic areas

Threats

  • Competition from established pharmaceutical companies
  • Regulatory setbacks
  • Unfavorable clinical trial outcomes

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • NVS
  • ALX
  • SAGE

Competitive Landscape

Skye Bioscience faces significant competition from established pharmaceutical companies with greater resources and approved products. Its success relies on demonstrating superior efficacy and safety with its cannabinoid-based therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by preclinical and clinical development milestones.

Future Projections: Future growth depends on the success of SBI-100 in clinical trials and potential future partnerships and approvals.

Recent Initiatives: Recent strategic initiatives include advancing SBI-100 through clinical trials and exploring additional cannabinoid therapeutic opportunities.

Summary

Skye Bioscience is an early-stage biopharmaceutical company focused on cannabinoid-based therapies. While the company's novel approach to treating glaucoma offers potential, its limited financial resources and early stage of development pose significant risks. Positive clinical trial results and strategic partnerships will be crucial for its future success. It needs to watch out for other companies with more funds or companies that might come out with the same type of therapy.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Skye Bioscience, Inc. Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2015-04-02
President, CEO, Secretary & Director Mr. Punit S. Dhillon B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.